| ID Source | ID |
|---|---|
| PubMed CID | 205058 |
| CHEMBL ID | 1230159 |
| CHEBI ID | 194633 |
| SCHEMBL ID | 1520041 |
| Synonym |
|---|
| CHEMBL1230159 |
| OPREA1_626164 |
| benzo(b)thiophene-3-acetic acid, 5-chloro- |
| brn 1244795 |
| 5-chlorobenzo(b)thiophene-3-acetic acid |
| IDI1_032498 |
| (5-chloro-1-benzothien-3-yl)acetic acid |
| AN-278/25047014 |
| MAYBRIDGE4_002620 |
| HMS1528H02 |
| cid205058 |
| 2-(5-chlorobenzo[b]thiophen-3-yl)acetic acid |
| 3n2 , |
| 2-(5-chloro-1-benzothiophen-3-yl)acetic acid |
| CHEBI:194633 |
| A811441 |
| 17266-30-7 |
| 5-18-06-00448 (beilstein handbook reference) |
| 5-chlorobenzo[b]thiophene-3-acetic acid |
| bdbm36500 |
| 2-(5-chlorobenzo[b]thiophen-3-yl)acetic acid, 1 |
| (5-chloro-1-benzothiophen-3-yl)acetic acid |
| BP-11257 |
| FT-0620310 |
| 5-chlorobenzo[b]thiophen-3-yl acetic acid |
| AKOS022181661 |
| SCHEMBL1520041 |
| (5-chloro-1-benzothien-3-yl)acetic acid # |
| DTXSID60169364 |
| benzo[b]thiophene-3-aceticacid,5-chloro- |
| mfcd00052308 |
| CCG-251690 |
| 2-(5-chlorobenzo[b]thiophen-3-yl)acetic acid, aldrichcpr |
| F16218 |
| AS-47810 |
| EN300-116007 |
| Q27453945 |
| Z1269130758 |
| SY143595 |
| Class | Description |
|---|---|
| 1-benzothiophenes | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Farnesyl pyrophosphate synthase | Homo sapiens (human) | IC50 (µMol) | 250,250.0000 | 0.0002 | 0.7109 | 9.3600 | AID1178321; AID1799420 |
| Kelch-like ECH-associated protein 1 | Homo sapiens (human) | Ki | 3,400.0000 | 0.5600 | 0.5600 | 0.5600 | AID1918093 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Kelch-like ECH-associated protein 1 | Homo sapiens (human) | Kd | 840.0000 | 1.0000 | 1.7667 | 2.4000 | AID1918095 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| AID1918095 | Binding affinity to Keap1 kelch domain (unknown origin) by surface plasmon resonance assay | 2022 | Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21 | Development of Noncovalent Small-Molecule Keap1-Nrf2 Inhibitors by Fragment-Based Drug Discovery. |
| AID1178321 | Inhibition of FPPS (unknown origin) | 2014 | Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16 | Biased and unbiased strategies to identify biologically active small molecules. |
| AID1918093 | Inhibition of recombinant human His-tagged Keap1 kelch domain (321 to 609 residues) expressed in Escherichia coli BL21(DE3) cells to Cy5-Nrf2 (unknown origin) protein-protein interaction incubated for 10 to 15 mins by fluorescence polarization assay | 2022 | Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21 | Development of Noncovalent Small-Molecule Keap1-Nrf2 Inhibitors by Fragment-Based Drug Discovery. |
| AID1799420 | Biophysical assay from Article 10.1038/nchembio.421: \\Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery.\\ | 2010 | Nature chemical biology, Sep, Volume: 6, Issue:9 | Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.64) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (14.29%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||